1783 related articles for article (PubMed ID: 25669445)
21. Physicochemical characterization and dissolution study of solid dispersions of Lovastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30.
Patel RP; Patel MM
Pharm Dev Technol; 2007; 12(1):21-33. PubMed ID: 17484141
[TBL] [Abstract][Full Text] [Related]
22. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
Chella N; Daravath B; Kumar D; Tadikonda RR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
[TBL] [Abstract][Full Text] [Related]
23. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier.
Khan AW; Kotta S; Ansari SH; Sharma RK; Ali J
Drug Dev Ind Pharm; 2015 May; 41(5):772-9. PubMed ID: 24669978
[TBL] [Abstract][Full Text] [Related]
24. Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan.
Lee JY; Kang WS; Piao J; Yoon IS; Kim DD; Cho HJ
Drug Des Devel Ther; 2015; 9():2745-56. PubMed ID: 26045660
[TBL] [Abstract][Full Text] [Related]
25. A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability.
Kim SJ; Lee HK; Na YG; Bang KH; Lee HJ; Wang M; Huh HW; Cho CW
Int J Pharm; 2019 Jan; 555():11-18. PubMed ID: 30448313
[TBL] [Abstract][Full Text] [Related]
26. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
27. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
Zhang X; Zhang T; Lan Y; Wu B; Shi Z
AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
[TBL] [Abstract][Full Text] [Related]
28. An Approach to Enhance Dissolution Rate of Tamoxifen Citrate.
SreeHarsha N; Hiremath JG; Chilukuri S; Aitha RK; Al-Dhubiab BE; Venugopala KN; Alzahrani AM; Meravanige G
Biomed Res Int; 2019; 2019():2161348. PubMed ID: 30800663
[TBL] [Abstract][Full Text] [Related]
29. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
Ha ES; Kim JS; Baek IH; Yoo JW; Jung Y; Moon HR; Kim MS
Drug Des Devel Ther; 2015; 9():4269-77. PubMed ID: 26345723
[TBL] [Abstract][Full Text] [Related]
30. Comparison of three different types of cilostazol-loaded solid dispersion: Physicochemical characterization and pharmacokinetics in rats.
Mustapha O; Kim KS; Shafique S; Kim DS; Jin SG; Seo YG; Youn YS; Oh KT; Yong CS; Kim JO; Choi HG
Colloids Surf B Biointerfaces; 2017 Jun; 154():89-95. PubMed ID: 28324691
[TBL] [Abstract][Full Text] [Related]
31. Enhancing the bioavailability of magnolol in rabbits using melting solid dispersion with polyvinylpyrrolidone.
Lin SP; Hou YC; Liao TY; Tsai SY
Drug Dev Ind Pharm; 2014 Mar; 40(3):330-7. PubMed ID: 23369092
[TBL] [Abstract][Full Text] [Related]
32. Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO₂: preparation, characterization and in vivo studies.
Zhang Z; Chen Y; Deng J; Jia X; Zhou J; Lv H
Int J Pharm; 2014 Apr; 465(1-2):306-16. PubMed ID: 24456672
[TBL] [Abstract][Full Text] [Related]
33. Poly(2-Ethyl-2-Oxazoline) as an Alternative to Poly(Vinylpyrrolidone) in Solid Dispersions for Solubility and Dissolution Rate Enhancement of Drugs.
Fael H; Ràfols C; Demirel AL
J Pharm Sci; 2018 Sep; 107(9):2428-2438. PubMed ID: 29859957
[TBL] [Abstract][Full Text] [Related]
34. Physicochemical characterization of artemether solid dispersions with hydrophilic carriers by freeze dried and melt methods.
Ansari MT; Karim S; Ranjha NM; Shah NH; Muhammad S
Arch Pharm Res; 2010 Jun; 33(6):901-10. PubMed ID: 20607495
[TBL] [Abstract][Full Text] [Related]
35. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
[TBL] [Abstract][Full Text] [Related]
36. Design of mirtazapine solid dispersion with different carriers' systems: optimization, in vitro evaluation, and bioavailability assessment.
Aldeeb RAE; Mahdy MAE; El-Nahas HM; Musallam AA
Drug Deliv Transl Res; 2023 Sep; 13(9):2340-2352. PubMed ID: 36940079
[TBL] [Abstract][Full Text] [Related]
37. Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change.
Oh DH; Park YJ; Kang JH; Yong CS; Choi HG
Drug Deliv; 2011 Jan; 18(1):46-53. PubMed ID: 20726805
[TBL] [Abstract][Full Text] [Related]
38. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
[TBL] [Abstract][Full Text] [Related]
39. Preparation of osthole-polymer solid dispersions by hot-melt extrusion for dissolution and bioavailability enhancement.
Yun F; Kang A; Shan J; Zhao X; Bi X; Li J; Di L
Int J Pharm; 2014 Apr; 465(1-2):436-43. PubMed ID: 24576810
[TBL] [Abstract][Full Text] [Related]
40. In vivo and in vitro evaluation of a solid dispersion system of gliclazide:PEG 6000.
Asyarie S; Rachmawati H
PDA J Pharm Sci Technol; 2007; 61(5):400-10. PubMed ID: 18047178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
